Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.56
-0.1600-9.30%
Post-market: 1.53-0.0300-1.92%19:48 EDT
Volume:3.12M
Turnover:4.97M
Market Cap:129.44M
PE:-0.54
High:1.69
Open:1.66
Low:1.52
Close:1.72
Loading ...

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

Zacks
·
20 Nov 2024

Editas Medicine upgraded to Outperform from In Line at Evercore ISI

TIPRANKS
·
07 Nov 2024

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire
·
06 Nov 2024

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%

Simply Wall St.
·
06 Nov 2024

Cautious Optimism for Editas Medicine Amid Strategic Milestones and Competitive Pressures

TIPRANKS
·
06 Nov 2024

Buy Rating for Editas Medicine Driven by Strategic Focus on In Vivo CRISPR Gene Editing and Intellectual Property Catalysts

TIPRANKS
·
06 Nov 2024

Editas Medicine’s Strong Financial Position and Promising Clinical Progress Drive Buy Rating

TIPRANKS
·
06 Nov 2024

Editas Medicine: Strategic Advancements and Promising Clinical Developments Justify Buy Rating

TIPRANKS
·
06 Nov 2024

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty

GuruFocus.com
·
06 Nov 2024

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

Zacks
·
06 Nov 2024

Editas Medicine Is Maintained at Overweight by Wells Fargo

Dow Jones
·
05 Nov 2024

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks
·
05 Nov 2024

Editas Medicine price target lowered to $11 from $17 at Stifel

TIPRANKS
·
05 Nov 2024

Editas Medicine Inc : Barclays Cuts Target Price to $5 From $7

THOMSON REUTERS
·
05 Nov 2024

Editas Medicine price target lowered to $7 from $9 at Wells Fargo

TIPRANKS
·
05 Nov 2024

Editas Medicine price target lowered to $5 from $7 at Barclays

TIPRANKS
·
05 Nov 2024